Podcast
Dr. Krambeck investigates efficacy of Trilogy and ShockPulse-SE lithotripters
Author(s):
“You have tradeoffs with every device that you use,” says Amy E. Krambeck, MD.
In this episode, Urology Times® Managing Editor Ben Saylor spoke with Amy E. Krambeck, MD. She discusses the recent Journal of Endourology study, "Multi-institutional prospective randomized control trial of novel intracorporeal lithotripters: ShockPulse-SE vs Trilogy trial," for which she served as senior author. Krambeck is a professor of urology at Northwestern University Feinberg School of Medicine in Chicago, Illinois.
Related Videos
Study results show CVAC 2.0 is safe, efficacious for wide range of kidney stones
Amir Patel, MD, on ureteral strictures following holmium vs TFL laser lithotripsy
Sarah Razavi, MD, discusses the physical toll of ureteroscopy on urologists
Joshua Heiman, MD, on phentermine plus topiramate for uric acid stone prevention
Investigators evaluate patient outcomes with silicone vs polyurethane stents
John Michael DiBianco, MD, on silicone vs polyurethane stents for patients with kidney stones
Khurshid Ghani, MD, on trial of stent omission following ureteroscopy
Endourologist discusses shared decision-making and laser lithotripsy
Ian Metzler, MD, on the role for telemedicine, digital health tools in stone disease
Perry Xu, MD, discusses PCNL’s role in the age of minimally invasive URS
Related Content
